Out-licensing
- Out-licensing
- View
Transdermal Fentanyl
Mechanism of action
Full description
Fentanyl is indicated for the management of severe pain in patients who require continuous opioid analgesia.
Indicated for chronic and intractable pain, Amarin developed a Fentanyl TDS using its drug-in-adhesive technology. Fentanyl TDS is currently commercialized in Germany, France, Spain, Italy, Greece, Hungary, Taiwan and Argentine under different brand names (Fentadolon®, Fentanyl Biogaran®, Dolforin®, Talnur®, etc) in four strengths. Presently, Fentanyl TDS is finalizing the Mutual Recognition Procedure in Europe and is in registration phase in Latinamerica.
Development status
Patent information
Europe (1503743), Mexico (245834) and India (216861). Two International Patent Applications were filed in 2003 (PCT/GB2003/002118). In 2011 a patent was granted in USA (8017146).
Type of business relationship sought
Amarin is seeking to license this product in USA and other territories.
Patent number
Related reports
Licensing contact
Company details
Amarin is engaged in the development of innovative pharmaceutical products using its proprietary topical and transdermal drug delivery technologies and know-how.
View profileRelated technologies
Related categories
- Industry sector
- Drug delivery
- Pharmaceutical / Generics
- Pharmaceutical
- Pharmaceutical / Prescription
- Drug delivery / Systemic
- Drug delivery / Systemic / Transdermal system
- Therapeutic target
- Central Nervous System
- Oncology
- Central Nervous System / Pain / Pain, acute
- Central Nervous System / Pain / Pain, AIDS-related
- Central Nervous System / Pain / Pain, back upper/lower
- Central Nervous System / Pain / Pain, cancer
- Central Nervous System / Pain / Pain, chronic
- Central Nervous System / Pain / Pain, inflammatory
- Central Nervous System / Pain / Pain, neuropathic
- Central Nervous System / Pain / Pain, post-operative
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us